SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Cambridge Antibody Technology Group
An SI Board Since December 1999
Posts SubjectMarks Bans
625 23 0
Emcee:  Jongmans Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
275This stock is getting killed on little volume (at least in US). A question fJFitnich-7/15/2002
274FWIW, I've seen the following estimates on D2E7 royalties in the last 30-60 JFitnich-6/18/2002
273From "3-5%", to "around 5%", to "5%". Who is to sakeokalani'nui-6/18/2002
272First Phase III Data for Abbott Laboratories' D2E7 (Adalimumab) Support Promnigel bates-6/14/2002
271Biosite's Dower Patent Upheld In Europe SAN DIEGO -(Dow Jones)- Biosite Incnigel bates-6/12/2002
270MELBOURN, England, May 20 /PRNewswire-FirstCall/ -- Professor Peter Garland, CATnigel bates-5/20/2002
269MELBOURN, England and ROCKVILLE, Md., May 20 /PRNewswire-FirstCall/ -- Cambridgenigel bates-5/20/2002
268Zyomyx Delivers First Protein Profiling Biochip(TM) Unit Message 17475078nigel bates-5/16/2002
267I hope CAT finds someone else to finance P3. They are going to need more than 5keokalani'nui-5/8/2002
266MELBOURN, England, May 8 /PRNewswire-FirstCall/ -- Cambridge Antibody Technologynigel bates-5/8/2002
265More positive comment on D2E7, repeating the hope for $1bn status... By: Danienigel bates-4/30/2002
264It's not a break up fee. When they originally bid for DRC, the two companienigel bates-4/30/2002
263What's the deal with the break-up fee? CAT is outbid, extends its offer andkeokalani'nui-4/30/2002
262To highlight the post: <i>The TRAIL-R1 human monoclonal antibody was madekeokalani'nui-4/30/2002
261Clinical Studies of a Human Monoclonal Antibody to TRAIL Receptor-1 Cleared by tnigel bates-4/30/2002
260First time I have seen (noticed?) specific reference to royalty rate. Guidance keokalani'nui-4/29/2002
259Abott, CAT arthritis drug shows promise in trials LONDON, April 29 (Reuters) - Anigel bates-4/29/2002
258Chuckle. The View from Malvern. From my uninformed view, it appears that the dscaram(o)uche-4/19/2002
257Nigel, My notes also show J695 in RA and "other automimmune". Miljenkeokalani'nui-4/19/2002
256<<, but CDP870 is coming and if the nurse can lift the syringe one month dMiljenko Zuanic-4/18/2002
255Certainly as informed as I am. <g> The $1bn figure wasn't mine, FWIW.nigel bates-4/18/2002
254Not all anti-TNF biologics are going to be $1b drugs. Enbrel is going to remainkeokalani'nui-4/18/2002
253No snickering, but a couple of quibbles. First, why $600m sales for D2E7, rathenigel bates-4/18/2002
252Anyone in Massachusetts in a couple of week's time ? Cambridge Healthtech Inigel bates-4/11/2002
251Human Genome Sciences Presentations at the American Association for Cancer Reseanigel bates-4/10/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News